Company Filing History:
Years Active: 2015
Title: The Innovative Contributions of David Furlano
Introduction
David Furlano is a notable inventor based in San Diego, CA. He has made significant contributions to the field of psychopharmacology through his innovative patent. His work focuses on enhancing the efficacy of antipsychotic treatments while minimizing side effects.
Latest Patents
David Furlano holds a patent for the "Combination of pimavanserin and risperidone for the treatment of psychosis." This patent highlights the combination of 5-HT2A inverse agonists or antagonists, such as pimavanserin, with antipsychotics like risperidone. The combination is shown to induce a rapid onset of antipsychotic action and increase the number of responders compared to therapy with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects. Additionally, the combinations are effective at decreasing the incidence of weight gain and increased glucose or prolactin levels caused by the antipsychotic.
Career Highlights
David Furlano is associated with Acadia Pharmaceuticals Inc., where he continues to contribute to advancements in psychiatric treatment. His innovative approach to combining medications has the potential to improve patient outcomes significantly.
Collaborations
David has worked alongside notable colleagues, including Perry Peters and Daun Bahr, who share his commitment to advancing medical science.
Conclusion
David Furlano's contributions to the field of psychopharmacology through his innovative patent demonstrate his dedication to improving treatment options for individuals with psychosis. His work exemplifies the impact of combining existing medications to enhance therapeutic efficacy while minimizing adverse effects.